Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | NPR3 | P17342 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588090 | 0.87 | CYP3A4 (0.52) | TDP1POLBMAPTCYP3A4NLRP3 | |
| SCHEMBL8125933 | 0.87 | CYP3A4 (0.52) | TDP1POLBMAPTCYP3A4NLRP3 | |
| SCHEMBL23093209 | 0.86 | NLRP3 (0.56) | CYP3A4NLRP3TBXAS1CYP2C9CYP1A2 | |
| SCHEMBL15180408 | 0.86 | NLRP3 (0.56) | CYP3A4NLRP3TBXAS1CYP2C9CYP1A2 | |
| SCHEMBL19945249 | 0.83 | ITGA4 (0.61) | TDP1POLBMAPTCYP3A4ITGA4 | |
| SCHEMBL19945248 | 0.83 | ITGA4 (0.61) | TDP1POLBMAPTCYP3A4ITGA4 | |
| SCHEMBL7378178 | 0.82 | CYP3A4 (0.48) | MAPTCYP3A4TBXAS1CYP2C9CYP1A2 | |
| SCHEMBL31754317 | 0.82 | TBXAS1 (0.47) | MAPTCYP3A4NLRP3TBXAS1CYP2C9 | |
| SCHEMBL25318441 | 0.81 | SLC7A5 (0.46) | MAPTCYP3A4TBXAS1CYP2C9CYP1A2 | |
| SCHEMBL30476014 | 0.81 | SLC7A5 (0.46) | MAPTCYP3A4TBXAS1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | TDP1 4285/4885POLB 3752/4885MAPT 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.